194 related articles for article (PubMed ID: 26979218)
1. [A new remedy for diarrheal irritable bowel syndrome].
Storr M
MMW Fortschr Med; 2016 Mar; 158(5):43. PubMed ID: 26979218
[No Abstract] [Full Text] [Related]
2. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
Med Lett Drugs Ther; 2016 Jan; 58(1485):4-5. PubMed ID: 26714241
[No Abstract] [Full Text] [Related]
3. Eluxadoline approved for irritable bowel syndrome with diarrhea.
Traynor K
Am J Health Syst Pharm; 2015 Jul; 72(13):1078. PubMed ID: 26092951
[No Abstract] [Full Text] [Related]
4. Τ Eluxadoline for IBS-D.
Drug Ther Bull; 2017 Aug; 55(8):91-92. PubMed ID: 28808082
[No Abstract] [Full Text] [Related]
5. Eluxadoline: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Jul; 75(11):1305-10. PubMed ID: 26149369
[TBL] [Abstract][Full Text] [Related]
6. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
Özdener AE; Rivkin A
Drug Des Devel Ther; 2017; 11():2827-2840. PubMed ID: 29033544
[TBL] [Abstract][Full Text] [Related]
7. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
8. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
Scarpellini E; Laterza L; Ianiro G; Tack J; Abenavoli L; Gasbarrini A
Expert Opin Pharmacother; 2016 Jul; 17(10):1395-402. PubMed ID: 27267380
[TBL] [Abstract][Full Text] [Related]
9. [Therapy for irritable bowel syndrome in sight?].
Frieling T
Dtsch Med Wochenschr; 2016 Apr; 141(8):526. PubMed ID: 27078238
[No Abstract] [Full Text] [Related]
10. The latest drug therapies for treating IBS. Longtime sufferers of irritable bowel syndrome have new options for relief.
Health After 50 Sci Am Consum Health; 2015 Dec; 27(12):3. PubMed ID: 27062744
[No Abstract] [Full Text] [Related]
11. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Nee J; Zakari M; Lembo AJ
Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
[TBL] [Abstract][Full Text] [Related]
12. Delta Variant: Expanding the Indication for Eluxadoline to Bile Acid Diarrhea.
Shah ED
Dig Dis Sci; 2022 Aug; 67(8):3481-3482. PubMed ID: 35122590
[No Abstract] [Full Text] [Related]
13. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
14. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.
Vera I; Júdez FJ
Rev Esp Enferm Dig; 2017 Nov; 109(11):788-794. PubMed ID: 28747053
[TBL] [Abstract][Full Text] [Related]
15. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Liu R; Staller K
Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
[TBL] [Abstract][Full Text] [Related]
16. The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea.
Abel JL; Carson RT; Andrae DA
Qual Life Res; 2019 Feb; 28(2):369-377. PubMed ID: 30267294
[TBL] [Abstract][Full Text] [Related]
17. Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder.
Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
Am J Gastroenterol; 2017 Oct; 112(10):1619-1620. PubMed ID: 28978951
[No Abstract] [Full Text] [Related]
18. Board Review Vignette: Irritable Bowel Syndrome.
Talley NJ
Am J Gastroenterol; 2016 Sep; 111(9):1223-5. PubMed ID: 27527743
[No Abstract] [Full Text] [Related]
19. Advancements in drug development for diarrhea-predominant irritable bowel syndrome.
Dothel G; Barbaro MR; Raschi E; Barbara G; De Ponti F
Expert Opin Investig Drugs; 2018 Mar; 27(3):251-263. PubMed ID: 29451407
[TBL] [Abstract][Full Text] [Related]
20. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
Keating GM
Drugs; 2017 Jun; 77(9):1009-1016. PubMed ID: 28493170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
